Unlike everyday supplements stocked in every health store, CJC-1295 reaches researchers through a specialist research supply market that Otago residents access almost entirely online. The practical advantage of this online-only market is that serious vendors differentiate entirely through their analytical documentation, giving researchers better verification tools than any local market ever offers. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. Use this guide to assess sourcing options methodically — the framework here work regardless of your location.
How CJC-1295 Works — Mechanisms & Research
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Otago researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Source CJC-1295 — Vendor Guide
Assessing CJC-1295 vendors starts with the COA: locate the batch-specific certificate before placing an order, not after. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone cannot verify molecular identity. Positive vendor signals beyond COA quality: documented vendor history spanning multiple years, responsive technical support who understand testing methodology, and shipping with desiccant and appropriate cold protection. Store lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the quantity required for your immediate research and keep the remainder frozen.
Order CJC-1295 — ships to Otago
COA-verified · International tracking · Research grade
CJC-1295 is supplied strictly for research applications and is not approved for human consumption by the FDA or equivalent agencies worldwide — all information here is provided for educational purposes. Proper handling of CJC-1295 requires careful sterile procedure — prep pad-cleaned septum, single-use needles, uncontaminated workspace — and cold chain maintenance from receipt through use. The most significant preventable safety hazard in CJC-1295 research is bacterial endotoxin from low-quality material — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. PubMed represent the most comprehensive research databases for CJC-1295 research; favour indexed journal publications over preprints over case reports or anecdotal evidence.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
